Tag : LENVATINIB

EMERALD-3 demonstrated that STRIDE + lenvatinib + TACE significantly improved PFS compared with TACE alone in unresectable embolization-eligible hepatocellular carcinoma. The regimen also showed a favorable OS trend, improved tumor response, and a manageable safety profile, supporting its potential as a new treatment option.

Bone metastases occur in approximately one-third of patients with advanced renal cell carcinoma and are associated with poor prognosis. This is partly due to RCC-driven immune dysregulation and the release of factors such as fibroblast growth factor and platelet-derived growth factor that promote osteoclast activation and bone resorption.

